AMRI acquires API maker Euticals

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

AMRI acquires API maker Euticals

INICIO/Noticias Farmacéuticas | Posted 24/06/2016 0 Post your comment

US-based Albany Molecular Research Inc (AMRI) announced on 5 May 2016 that it had entered into a definitive agreement to buy Prime European Therapeuticals, also known as Euticals.

Euticals is a privately held company headquartered in Lodi, Italy specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). It operates a network of API facilities primarily in France, Germany, Italy and the US.

AMRI will pay approximately US$358 million (Euros 315 million) for the API maker, which will be made up of shares of AMRI common stock, cash and a seller note.

The API portfolio from Euticals includes 50 active US Drug Master Files (DMFs), 17 EU Certificates of Suitability (COS) or Compliance with the European Pharmacopeia (CEP), 13 Japanese DMFs and six South Korean DMFs; with several APIs having filings in more than one of these areas and over two dozen other international filings.

The move is set to expand AMRI’s presence in Europe and, according to the company, will position it as one of the largest independent developers and suppliers of APIs. It will also expand AMRI’s expertise in multiple areas, including sterile APIs, steroids, generics, fermentation, controlled substances and monobactams. In addition, AMRI also expects the large base of over 400 customers from Euticals will provide the company with a number of new large pharma, biotech and generics partners, further extending the company’s global reach and diversifying its revenue.

Related article
Major shake-up of API import rules in Europe

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: AMRI